FRANKLIN, Tenn. / Mar 11, 2024 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the Barclays 26th Annual Global Healthcare Conference, which is being held March 12 - 14, 2024, in Miami, Florida. In connection with the conference, there will be a webcast of the Company’s presentation available on the Company’s website starting at 10:45 a.m. Eastern Time/9:45 a.m. Central Time on Wednesday, March 13, 2024.
The live webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investor Relations” link. A replay of the presentation will also be available on the Company’s website for thirty days.
About Acadia Healthcare Company, Inc.
Acadia is a leading provider of behavioral healthcare services across the United States. As of December 31, 2023, Acadia operated a network of 253 behavioral healthcare facilities with approximately 11,200 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
| Last Trade: | US$14.49 |
| Daily Change: | -0.21 -1.43 |
| Daily Volume: | 812,221 |
| Market Cap: | US$1.310B |
November 05, 2025 August 05, 2025 May 12, 2025 February 27, 2025 October 30, 2024 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load